Gilead secures new anti-cancer therapy in $4.9bn deal

02-03-2020

Rory O'Neill

Gilead secures new anti-cancer therapy in $4.9bn deal

II Studio / Shutterstock.com

Gilead Sciences has agreed a $4.9 billion deal to buy California-based immuno-oncology company Forty Seven.


Gilead Sciences, Forty Seven, Daniel O’Day, magrolimab, Descovy, Truvada, PrEP, immuno-oncology

LSIPR